- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) early breast cancer
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Ribociclib – July 2025
Ribociclib; Tablet 200 mg; Kisqali®
Last updated
9 July 2025